FDA’s Generics Office Loses Another Director As Geba Makes Quick Exit
This article was originally published in The Pink Sheet Daily
Executive Summary
Gregory Geba will step down March 15, saying ongoing organizational changes created challenges to implementing his vision; CDER Director Janet Woodcock will run the office during the nationwide search for a replacement.
You may also be interested in...
FDA’s Office Of Generic Drugs Gets New Permanent Director And Oversight Designee
Iilun Murphy, a 15-year agency veteran, takes helm of OGD. Jacqueline Corrigan-Curay to assume oversight of the office and report to CDER director.
Next US FDA Generics Leader Must Have ‘Frank Conversations’ With Colleagues, Industry, Former OGD Director Says
Susan Rosencrance, who helped negotiate GDUFA III, will take over as acting director of the Office of Generic Drugs following Sally Choe’s departure on 8 October. Former OGD head Uhl says the director needs to be the ‘number one advocate for the generic drug program inside the agency.’
US FDA Again Looks Outside Generic Drugs Office For New Director
Sally Choe, who has been working in the Office of Translational Sciences, will take over for Kathleen Uhl in March.